
Master thymic peptide of the immune system — modulates T-lymphocyte maturation. Approved in 35+ countries for hepatitis and as immunomodulator.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminus, isolated in 1977 by Allan Goldstein from thymosin fraction 5 of calf thymus and today produced synthetically. Together with thymosin β4 it is the best-characterized thymic peptide, but its function differs: while β4 regulates actin and cell motility, α1 is an immunomodulator acting on innate and adaptive immunity. Its blood concentration is low and declines with age.
The best-established mechanism is activation of Toll-like receptors TLR2 and TLR9 on dendritic cells, which induces their maturation, IL-12 and interferon production and, downstream, differentiation of T lymphocytes toward Th1 and regulatory profiles. It also increases MHC class I expression on infected or tumor cells, favors NK activity and modulates IL-10. The result is a rebalancing of the immune response rather than indiscriminate stimulation, which explains its study as an adjuvant.
Under the name Zadaxin (SciClone) it is approved in more than thirty countries — Italy, China, much of Asia and Latin America — for chronic hepatitis B and C, as a vaccine adjuvant in the immunocompromised and in some cancers in combination; it holds no FDA approval, although it has orphan-drug designations. Its half-life is about two hours and its tolerability in trials has been good. Renova's product is strictly for research.
| Class | Immunomodulatory thymic peptide (thymalfasin, INN) |
| Sequence | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN (28 aa, N-acetylated) |
| CAS | 62304-98-7 |
| Discovery | Allan Goldstein, 1977 (thymosin fraction 5) |
| Mechanism | TLR2/TLR9 agonist on dendritic cells → IL-12, IFN, Th1 differentiation; ↑ MHC-I; NK activity |
| Half-life | ≈ 2 hours |
| Regulatory status | Approved as Zadaxin in > 30 countries (hepatitis B/C, adjuvant); no FDA approval; Renova product is RUO |
| Properties | Highly water-soluble acidic peptide; no cysteine or methionine |
They share only the name and the organ of origin. Alpha-1 is a 28-amino-acid peptide that regulates the immune system through Toll-like receptors; beta-4 is a 43-amino-acid protein that sequesters actin and takes part in cell migration and tissue repair. They are different research lines.
As Zadaxin, in more than thirty countries: Italy, China and much of Asia and Latin America, for chronic hepatitis B and C, as a vaccine adjuvant in immunocompromised patients and in some cancers in combination. It has no FDA approval. Renova's product is not Zadaxin; it is research material.
It activates TLR2 and TLR9 receptors on dendritic cells, which mature and produce IL-12 and interferon; that steers T lymphocytes toward Th1 and regulatory responses and increases MHC class I expression on infected cells. It is a modulator that rebalances the response, not a nonspecific stimulant.
No. Thymalin is a bovine extract of undefined composition with almost exclusively Russian evidence; thymosin alpha-1 is a defined synthetic peptide with regulatory approval in dozens of countries and international trials. Our thymosin alpha-1 guide details its clinical base.
Related reading: Thymosin Alpha-1: The Thymic Immunomodulating Peptide · LL-37: The Human Antimicrobial Peptide
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty